News
-
-
-
COMMUNIQUÉ DE PRESSE
Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region
Lotus Pharmaceutical partners with Formycon AG for commercialization of Keytruda biosimilar FYB206 in Asia-Pacific region, marking a key step in Formycon's global strategy -
-
-
COMMUNIQUÉ DE PRESSE
FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco® – Strengthening US Presence with Zydus as Commercialization Partner
FDA approves Formycon's Nufymco® as interchangeable Ranibizumab Biosimilar, partnering with Zydus for commercialization in the US, expanding access to retinal therapies -
-
-
COMMUNIQUÉ DE PRESSE
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
Formycon AG and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada. Agreement includes milestone payments, development progress, and upcoming data release -
